DE69521208T2 - Morpholinderivate und ihre verwendung als therapeutische mittel - Google Patents
Morpholinderivate und ihre verwendung als therapeutische mittelInfo
- Publication number
- DE69521208T2 DE69521208T2 DE69521208T DE69521208T DE69521208T2 DE 69521208 T2 DE69521208 T2 DE 69521208T2 DE 69521208 T DE69521208 T DE 69521208T DE 69521208 T DE69521208 T DE 69521208T DE 69521208 T2 DE69521208 T2 DE 69521208T2
- Authority
- DE
- Germany
- Prior art keywords
- 4alkyl
- pct
- hydrogen
- 4alkoxy
- hydroxy
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- YNAVUWVOSKDBBP-UHFFFAOYSA-N Morpholine Chemical class C1COCCN1 YNAVUWVOSKDBBP-UHFFFAOYSA-N 0.000 title 1
- 239000003814 drug Substances 0.000 title 1
- 229940124597 therapeutic agent Drugs 0.000 title 1
- 229910052739 hydrogen Inorganic materials 0.000 abstract 4
- 239000001257 hydrogen Substances 0.000 abstract 4
- 125000004435 hydrogen atom Chemical group [H]* 0.000 abstract 4
- 125000002887 hydroxy group Chemical group [H]O* 0.000 abstract 3
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 abstract 2
- 125000000229 (C1-C4)alkoxy group Chemical group 0.000 abstract 2
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 abstract 2
- 125000006272 (C3-C7) cycloalkyl group Chemical group 0.000 abstract 2
- 150000001875 compounds Chemical class 0.000 abstract 2
- 229910052760 oxygen Inorganic materials 0.000 abstract 2
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 abstract 2
- 125000006413 ring segment Chemical group 0.000 abstract 2
- 229910052717 sulfur Inorganic materials 0.000 abstract 2
- 241000689227 Cora <basidiomycete fungus> Species 0.000 abstract 1
- 206010061218 Inflammation Diseases 0.000 abstract 1
- 208000019695 Migraine disease Diseases 0.000 abstract 1
- 208000002193 Pain Diseases 0.000 abstract 1
- 206010036376 Postherpetic Neuralgia Diseases 0.000 abstract 1
- 206010047700 Vomiting Diseases 0.000 abstract 1
- 125000003118 aryl group Chemical group 0.000 abstract 1
- 125000004432 carbon atom Chemical group C* 0.000 abstract 1
- 125000004122 cyclic group Chemical group 0.000 abstract 1
- 125000005842 heteroatom Chemical group 0.000 abstract 1
- 125000000623 heterocyclic group Chemical group 0.000 abstract 1
- 125000002883 imidazolyl group Chemical group 0.000 abstract 1
- 230000004054 inflammatory process Effects 0.000 abstract 1
- 206010027599 migraine Diseases 0.000 abstract 1
- 230000002265 prevention Effects 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 229920006395 saturated elastomer Polymers 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D265/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom and one oxygen atom as the only ring hetero atoms
- C07D265/28—1,4-Oxazines; Hydrogenated 1,4-oxazines
- C07D265/30—1,4-Oxazines; Hydrogenated 1,4-oxazines not condensed with other rings
- C07D265/32—1,4-Oxazines; Hydrogenated 1,4-oxazines not condensed with other rings with oxygen atoms directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/08—Bridged systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F7/00—Compounds containing elements of Groups 4 or 14 of the Periodic System
- C07F7/02—Silicon compounds
- C07F7/08—Compounds having one or more C—Si linkages
- C07F7/18—Compounds having one or more C—Si linkages as well as one or more C—O—Si linkages
- C07F7/1804—Compounds having Si-O-C linkages
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB9416427A GB9416427D0 (en) | 1994-08-15 | 1994-08-15 | Therapeutic agents |
| GBGB9509605.3A GB9509605D0 (en) | 1995-05-11 | 1995-05-11 | Therapeutic agents |
| PCT/GB1995/001868 WO1996005181A1 (en) | 1994-08-15 | 1995-08-07 | Morpholine derivatives and their use as therapeutic agents |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| DE69521208D1 DE69521208D1 (de) | 2001-07-12 |
| DE69521208T2 true DE69521208T2 (de) | 2001-11-08 |
Family
ID=26305450
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DE69521208T Expired - Fee Related DE69521208T2 (de) | 1994-08-15 | 1995-08-07 | Morpholinderivate und ihre verwendung als therapeutische mittel |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US5824678A (de) |
| EP (1) | EP0777659B1 (de) |
| JP (1) | JP2002502351A (de) |
| AT (1) | ATE201866T1 (de) |
| AU (1) | AU691327B2 (de) |
| CA (1) | CA2195972A1 (de) |
| DE (1) | DE69521208T2 (de) |
| DK (1) | DK0777659T3 (de) |
| ES (1) | ES2157337T3 (de) |
| GR (1) | GR3036006T3 (de) |
| IL (1) | IL114865A (de) |
| PT (1) | PT777659E (de) |
| WO (1) | WO1996005181A1 (de) |
Families Citing this family (68)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6117855A (en) | 1996-10-07 | 2000-09-12 | Merck Sharp & Dohme Ltd. | Use of a NK-1 receptor antagonist and an antidepressant and/or an anti-anxiety agent |
| JP2001504851A (ja) * | 1996-12-02 | 2001-04-10 | メルク シヤープ エンド ドーム リミテツド | 性的機能不全の治療のためのｎｋ−１受容体拮抗薬の使用 |
| CA2273853A1 (en) * | 1996-12-02 | 1998-06-11 | Merck Sharp & Dohme Limited | Use of nk-1 receptor antagonists for treating cognitive disorders |
| CA2273807A1 (en) * | 1996-12-02 | 1998-06-11 | Merck Sharp & Dohme Limited | Use of nk-1 receptor antagonists for treating schizophrenic disorders |
| US6114315A (en) * | 1996-12-02 | 2000-09-05 | Merck Sharp & Dohme Ltd. | Use of NK-1 receptor antagonists for treating major depressive disorders with anxiety |
| US6100256A (en) * | 1996-12-02 | 2000-08-08 | Merck Sharp & Dohme Ltd. | Use of NK-1 receptors antagonists for treating schizophrenic disorders |
| JP2001507678A (ja) * | 1996-12-02 | 2001-06-12 | メルク シヤープ エンド ドーム リミテツド | 運動障害の治療のためのｎｋ−１受容体拮抗薬の使用 |
| AU733855B2 (en) * | 1996-12-02 | 2001-05-31 | Merck Sharp & Dohme Limited | Use of NK-1 receptor antagonists for treating major depressive disorders |
| EP0942729B1 (de) * | 1996-12-02 | 2004-09-01 | MERCK SHARP & DOHME LTD. | Die verwendung von nk-1 rezeptor antagonisten für die behandlungen von stress störungen |
| US6613765B1 (en) | 1996-12-02 | 2003-09-02 | Merck Sharp & Dohme Limited | Use of NK-1 receptor antagonists for treating major depressive disorders |
| EP0941093B1 (de) * | 1996-12-02 | 2005-02-09 | MERCK SHARP & DOHME LTD. | Verwendung von nk-1 rezeptorantagonisten zur behandlung von schweren depressionen, die von angstzuständen begleitet werden |
| CA2273856A1 (en) * | 1996-12-02 | 1998-06-11 | Merck Sharp & Dohme Limited | Use of nk-1 receptor antagonists for treating bipolar disorders |
| WO1998024439A1 (en) * | 1996-12-02 | 1998-06-11 | Merck Sharp & Dohme Limited | Use of nk-1 receptor antagonists for treating severe anxiety disorders |
| US5977104A (en) * | 1996-12-02 | 1999-11-02 | Merck Sharp & Dohme Ltd. | Use of NK-1 receptor antagonists for treating bipolar disorders |
| JP2001504853A (ja) * | 1996-12-02 | 2001-04-10 | メルク シヤープ エンド ドーム リミテツド | 物質使用障害の治療のためのｎｋ−１受容体拮抗薬の使用 |
| EP0977572A1 (de) * | 1997-04-24 | 2000-02-09 | Merck Sharp & Dohme Ltd. | Verwendung von nk-1 rezeptor-antagonisten zur behandlung von essstörungen |
| AU738047B2 (en) * | 1997-08-04 | 2001-09-06 | Merck Sharp & Dohme Limited | Use of NK-1 receptor antagonists for treating mania |
| WO1999007375A1 (en) * | 1997-08-04 | 1999-02-18 | Merck Sharp & Dohme Limited | Use of nk-1 receptor antagonists for treating aggressive behaviour disorders |
| GB9716463D0 (en) * | 1997-08-04 | 1997-10-08 | Merck Sharp & Dohme | Therapeutic agents |
| GB9716457D0 (en) * | 1997-08-04 | 1997-10-08 | Merck Sharp & Dohme | Therapeutic agents |
| US6271230B1 (en) | 1997-12-01 | 2001-08-07 | Merck Sharp & Dohme Limited | Use of NK-1 receptor antagonists for treating cognitive disorders |
| US6156749A (en) * | 1997-12-01 | 2000-12-05 | Merck Sharp & Dohme Limited | Use of NK-1 receptor antagonists for treating movement disorders |
| US6087348A (en) * | 1997-12-01 | 2000-07-11 | Merck Sharp & Dohme Ltd. | Use of NK-1 receptor antagonists for treating stress disorders |
| AU1230000A (en) * | 1998-10-30 | 2000-05-22 | Merck & Co., Inc. | Linear process for the preparation of a morpholine compound |
| GB9907571D0 (en) * | 1999-04-06 | 1999-05-26 | Zeneca Ltd | Compounds |
| US7279547B2 (en) * | 2000-02-10 | 2007-10-09 | University Of Connecticut | Insecticidal compounds and methods for selection thereof |
| WO2001068620A1 (en) | 2000-03-13 | 2001-09-20 | Ortho-Mcneil Pharmaceutical, Inc. | Novel cyclopentene derivatives useful as antagonists of the motilin receptor |
| US6423714B2 (en) | 2000-03-13 | 2002-07-23 | Ortho Mcneil-Pharmaceutical, Inc.. | Cyclohexene derivatives useful as antagonists of the motilin receptor |
| WO2001068622A1 (en) | 2000-03-13 | 2001-09-20 | Ortho-Mcneil Pharmaceutical, Inc. | Novel cyclobutene derivatives useful as antagonists of the motilin receptor |
| AU2003243353A1 (en) * | 2002-05-29 | 2003-12-19 | The Regents Of The University Of California | Antagonizing nk1 receptors inhibits consumption of substances of abuse |
| ZA200701232B (en) | 2004-07-15 | 2008-08-27 | Amr Technology Inc | Aryl-and heteroaryl-substituted tetrahydroisoquinolines and use thereof to block reuptake of norepinephrine, dopamine and serotonin |
| ES2382814T3 (es) | 2005-05-17 | 2012-06-13 | Merck Sharp & Dohme Ltd. | Ácido cis-4-[(4-clorofenil)sulfonil]-4-(2,5-difluorofenil)ciclohexanopropanoico para el tratamiento del cáncer |
| EP1904069B1 (de) | 2005-07-15 | 2018-06-13 | Albany Molecular Research, Inc. | Aryl- und heteroarylsubstituierte tetrahydrobenzazepine und verwendung damit zur wiederaufnahmeblockierung von norepinephrin, dopamin und serotonin |
| US8293900B2 (en) | 2005-09-29 | 2012-10-23 | Merck Sharp & Dohme Corp | Acylated spiropiperidine derivatives as melanocortin-4 receptor modulators |
| GB0603041D0 (en) | 2006-02-15 | 2006-03-29 | Angeletti P Ist Richerche Bio | Therapeutic compounds |
| CA2664113C (en) | 2006-09-22 | 2013-05-28 | Merck & Co., Inc. | Use of platencin and platensimycin as fatty acid synthesis inhibitors to treat obesity, diabetes and cancer |
| US20110218176A1 (en) | 2006-11-01 | 2011-09-08 | Barbara Brooke Jennings-Spring | Compounds, methods, and treatments for abnormal signaling pathways for prenatal and postnatal development |
| BRPI0806245B1 (pt) | 2007-01-10 | 2022-01-25 | Msd Italia S.R.L. | Compostos de fórmula i e seus usos |
| KR20090112722A (ko) | 2007-01-24 | 2009-10-28 | 글락소 그룹 리미티드 | 3,5-디아미노-6-(2,3-디클로로페닐)-1,2,4-트리아진 또는 ｒ(-)-2,4-디아미노-5-(2,3-디클로로페닐)-6-플루오로메틸 피리미딘 및 ｎｋ1을 포함하는 제약 조성물 |
| CA2682727C (en) | 2007-04-02 | 2016-03-22 | Banyu Pharmaceutical Co., Ltd. | Indoledione derivative |
| EP2170076B1 (de) | 2007-06-27 | 2016-05-18 | Merck Sharp & Dohme Corp. | 4-carboxybenzylamino-derivate als histondeacetylase-hemmer |
| US8598184B2 (en) | 2008-03-03 | 2013-12-03 | Tiger Pharmatech | Protein kinase inhibitors |
| US9156812B2 (en) | 2008-06-04 | 2015-10-13 | Bristol-Myers Squibb Company | Crystalline form of 6-[(4S)-2-methyl-4-(2-naphthyl)-1,2,3,4-tetrahydroisoquinolin-7-yl]pyridazin-3-amine |
| US8691825B2 (en) | 2009-04-01 | 2014-04-08 | Merck Sharp & Dohme Corp. | Inhibitors of AKT activity |
| CA2760837C (en) | 2009-05-12 | 2018-04-03 | Albany Molecular Research, Inc. | 7-([1,2,4]triazolo[1,5-.alpha.]pyridin-6-yl)-4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydroisoquinoline and use thereof |
| KR20120034644A (ko) | 2009-05-12 | 2012-04-12 | 알바니 몰레큘라 리써치, 인크. | 아릴, 헤테로아릴, 및 헤테로사이클 치환된 테트라하이드로이소퀴놀린 및 이의 용도 |
| CN102638982B (zh) | 2009-05-12 | 2015-07-08 | 百时美施贵宝公司 | (S)-7-([1,2,4]三唑并[1,5-a]吡啶-6-基)-4-(3,4-二氯苯基)-1,2,3,4-四氢异喹啉的晶型及其用途 |
| WO2011046771A1 (en) | 2009-10-14 | 2011-04-21 | Schering Corporation | SUBSTITUTED PIPERIDINES THAT INCREASE p53 ACTIVITY AND THE USES THEREOF |
| WO2011163330A1 (en) | 2010-06-24 | 2011-12-29 | Merck Sharp & Dohme Corp. | Novel heterocyclic compounds as erk inhibitors |
| CA2805265A1 (en) | 2010-08-02 | 2012-02-09 | Merck Sharp & Dohme Corp. | Rna interference mediated inhibition of catenin (cadherin-associated protein), beta 1 (ctnnb1) gene expression using short interfering nucleic acid (sina) |
| WO2012024170A2 (en) | 2010-08-17 | 2012-02-23 | Merck Sharp & Dohme Corp. | RNA INTERFERENCE MEDIATED INHIBITION OF HEPATITIS B VIRUS (HBV) GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA) |
| US8883801B2 (en) | 2010-08-23 | 2014-11-11 | Merck Sharp & Dohme Corp. | Substituted pyrazolo[1,5-a]pyrimidines as mTOR inhibitors |
| US8946216B2 (en) | 2010-09-01 | 2015-02-03 | Merck Sharp & Dohme Corp. | Indazole derivatives useful as ERK inhibitors |
| EP2615916B1 (de) | 2010-09-16 | 2017-01-04 | Merck Sharp & Dohme Corp. | Kondensierte pyrazolderivate als neue erk-hemmer |
| WO2012058210A1 (en) | 2010-10-29 | 2012-05-03 | Merck Sharp & Dohme Corp. | RNA INTERFERENCE MEDIATED INHIBITION OF GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACIDS (siNA) |
| WO2012087772A1 (en) | 2010-12-21 | 2012-06-28 | Schering Corporation | Indazole derivatives useful as erk inhibitors |
| JP2014514321A (ja) | 2011-04-21 | 2014-06-19 | メルク・シャープ・アンド・ドーム・コーポレーション | インスリン様増殖因子１受容体阻害剤 |
| US9023865B2 (en) | 2011-10-27 | 2015-05-05 | Merck Sharp & Dohme Corp. | Compounds that are ERK inhibitors |
| US20150299696A1 (en) | 2012-05-02 | 2015-10-22 | Sirna Therapeutics, Inc. | SHORT INTERFERING NUCLEIC ACID (siNA) COMPOSITIONS |
| WO2014052563A2 (en) | 2012-09-28 | 2014-04-03 | Merck Sharp & Dohme Corp. | Novel compounds that are erk inhibitors |
| MX363243B (es) | 2012-11-28 | 2019-03-14 | Merck Sharp & Dohme | Composiciones para tratar cáncer y usos de dichas composiciones. |
| RU2690663C2 (ru) | 2012-12-20 | 2019-06-05 | Мерк Шарп И Доум Корп. | Замещенные имидазопиридины в качестве ингибиторов hdm2 |
| US9540377B2 (en) | 2013-01-30 | 2017-01-10 | Merck Sharp & Dohme Corp. | 2,6,7,8 substituted purines as HDM2 inhibitors |
| US20160194368A1 (en) | 2013-09-03 | 2016-07-07 | Moderna Therapeutics, Inc. | Circular polynucleotides |
| US10947234B2 (en) | 2017-11-08 | 2021-03-16 | Merck Sharp & Dohme Corp. | PRMT5 inhibitors |
| WO2020033284A1 (en) | 2018-08-07 | 2020-02-13 | Merck Sharp & Dohme Corp. | Prmt5 inhibitors |
| EP3833668A4 (de) | 2018-08-07 | 2022-05-11 | Merck Sharp & Dohme Corp. | Prmt5-inhibitoren |
| CN111004190A (zh) * | 2019-11-08 | 2020-04-14 | 广州曼翔医药有限公司 | 一种阿瑞匹坦中间体的制备方法 |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0600952B1 (de) * | 1991-08-20 | 1996-04-17 | MERCK SHARP & DOHME LTD. | Azacyclische verbindungen, verfahren zu ihrer herstellung und diese enthaltende pharmazeutische zubereitungen |
| CA2099233A1 (en) * | 1992-06-29 | 1993-12-30 | Conrad P. Dorn | Morpholine and thiomorpholine tachykinin receptor antagonists |
| IL111960A (en) * | 1993-12-17 | 1999-12-22 | Merck & Co Inc | Morpholines and thiomorpholines their preparation and pharmaceutical compositions containing them |
| PL181214B1 (pl) * | 1993-12-29 | 2001-06-29 | Merck Sharp & Dohme | Podstawione związki morfolinowe, sposób ich wytwarzania oraz zawierające je kompozycje farmaceutyczne |
-
1995
- 1995-08-07 DK DK95927862T patent/DK0777659T3/da active
- 1995-08-07 AT AT95927862T patent/ATE201866T1/de not_active IP Right Cessation
- 1995-08-07 US US08/793,186 patent/US5824678A/en not_active Expired - Fee Related
- 1995-08-07 DE DE69521208T patent/DE69521208T2/de not_active Expired - Fee Related
- 1995-08-07 EP EP95927862A patent/EP0777659B1/de not_active Expired - Lifetime
- 1995-08-07 CA CA002195972A patent/CA2195972A1/en not_active Abandoned
- 1995-08-07 JP JP50710696A patent/JP2002502351A/ja not_active Withdrawn
- 1995-08-07 WO PCT/GB1995/001868 patent/WO1996005181A1/en active IP Right Grant
- 1995-08-07 PT PT95927862T patent/PT777659E/pt unknown
- 1995-08-07 AU AU31855/95A patent/AU691327B2/en not_active Ceased
- 1995-08-07 ES ES95927862T patent/ES2157337T3/es not_active Expired - Lifetime
- 1995-08-08 IL IL11486595A patent/IL114865A/xx active IP Right Grant
-
2001
- 2001-06-07 GR GR20010400305T patent/GR3036006T3/el not_active IP Right Cessation
Also Published As
| Publication number | Publication date |
|---|---|
| US5824678A (en) | 1998-10-20 |
| EP0777659A1 (de) | 1997-06-11 |
| CA2195972A1 (en) | 1996-02-22 |
| IL114865A0 (en) | 1995-12-08 |
| WO1996005181A1 (en) | 1996-02-22 |
| GR3036006T3 (en) | 2001-09-28 |
| AU3185595A (en) | 1996-03-07 |
| DE69521208D1 (de) | 2001-07-12 |
| PT777659E (pt) | 2001-09-28 |
| EP0777659B1 (de) | 2001-06-06 |
| ES2157337T3 (es) | 2001-08-16 |
| ATE201866T1 (de) | 2001-06-15 |
| IL114865A (en) | 1999-06-20 |
| JP2002502351A (ja) | 2002-01-22 |
| AU691327B2 (en) | 1998-05-14 |
| DK0777659T3 (da) | 2001-09-03 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ATE201866T1 (de) | Morpholinderivate und ihre verwendung als therapeutische mittel | |
| ES2128791T3 (es) | Derivados espirocetales, composiciones que los contienen y su uso como agentes terapeuticos. | |
| ATE360631T1 (de) | Azabicyclische heterocyclen als modulatoren des cannabinoidrezeptors | |
| ATE360630T1 (de) | Azabicyclische heterocyclen als modulatoren des cannabinoidrezeptors | |
| ES2159558T3 (es) | Derivados de guanidina como inhibidores del intercambio na+/h+ en las celulas. | |
| MX9707453A (es) | Derivados de quinazolina. | |
| ES2141174T3 (es) | 4-arilmetiloximetil piperidinas como antagonistas de taquiquinina. | |
| PL350123A1 (en) | Tetrahydropyran derivatives and their use as therapeutic agents | |
| ES2098947T3 (es) | Derivados de beta,beta-dimetil-4-piperidinoetanamina como inhibidores de la biosintesis del colesterol. | |
| ES2135769T3 (es) | Derivados de isotiourea como inhibidores de no-sintasa. | |
| DE69511544D1 (de) | Amidderivate und ihre therapeutische verwendung | |
| JO2231B1 (en) | Derivatives of Trahydroperan and its use as a therapeutic agent | |
| AU1799297A (en) | Spiro-ketal derivatives and their use as therapeutic agents | |
| DE69413831T2 (de) | Phenoxyphenylcyclopentenyl-hydroxyharnstoffe |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| 8364 | No opposition during term of opposition | ||
| 8339 | Ceased/non-payment of the annual fee |